Tiger Brokers

  • Quotes
  • Products
    • Cash Boost Account
    • US Stocks
    • US Fractional Shares
    • HK Stocks
    • China A-shares
    • Options
    • Futures
    • US Treasury
    • Auto-invest
    • Fixed Coupon Notes
    • Tiger BOSS Debit Card
    • Fund Mall
    • Tiger Vault
    • Tiger Open Platform
    • Wealth
  • Pricing
    • Prime
      • Stocks & ETFs
      • Options, Warrants & CBBCs
      • Futures
      • Bonds
      • Fund Mall
    • Cash Boost
      • Stocks & ETFs
    • Financing Interest Rates
  • Promotions
  • Help
    • Account Operations
      • How to Open an Account?
      • Account Opening Documents
      • Account Types Available
    • Transfer & Pay
      • Account Funding
      • DDA Fast Deposit
      • Funds Withdrawal
      • Shares Transfer-in
      • Shares Transfer-out
      • Currency Conversion
    • Products & Trading
      • Products Available
      • Order Types
      • Trading Rules
      • Declaration
    • Margin Trading & Short Selling
      • Margin & Leverage
      • Risk Management
      • Short Selling Risk
    • Fund Mall
      • Open a fund account and transaction
    • Cash Boost Account
      • Cash Boost Account FAQ
      • How to Open Cash Boost Account
      • How to Contra Trade using Cash Boost Account
      • How to link your CDP Securities Account
    • Tiger Boss Debit Card
      • Frequently Asked Questions
      • Fees of the Debit card
      • How to Top-up
      • How to use my Debit card
    • Tiger Vault
      • Features of Tiger Vault
      • Transaction Fees
    • Statement
      • Statement
      • Dividends
  • Learn
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
  • Careers
    • L.E.A.P Programme
    • Investment Representative
    • Careers Portal
  • LOGIN
  • SIGN UP
US StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

ITT Inc.

149.41
+6.244.36%
Post-market: 149.410.00000.00%16:20 EDT
Volume:499.21K
Turnover:74.49M
Market Cap:11.76B
PE:23.79
High:150.04
Open:148.13
Low:147.50
Close:143.17
Loading ...
OverviewCompanyNewsFilings

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…

Zacks Small Cap Research
·
28 Mar

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

GlobeNewswire
·
27 Mar

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

GlobeNewswire
·
24 Mar

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Zacks
·
14 Mar

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

GlobeNewswire
·
11 Mar

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

Business Wire
·
04 Mar

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…

Zacks Small Cap Research
·
28 Feb
More

Analyst Rate

Buy
Buy
76.92%
Hold
23.08%
Sell
0.00%

Corporate Actions

Ex-dividend Date
Jun 02, 2025 Dividend Per Share 0.351 USD
Financial Report Announcement
May 01, 2025 Pre-Market
Financial Report Announcement
Apr 10, 2025 Pre-Market
Ex-dividend Date
Mar 06, 2025 Dividend Per Share 0.351 USD
Financial Report Announcement
Feb 06, 2025 Pre-Market

Dividend History

Ex-DateDividend
2015-06-100.1183
2015-09-090.1183
2015-12-090.1183
2016-03-090.124
2016-06-080.124

Valuation Analysis

21.91
Current
36.80
Sector Average
49.63%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
21.91
Maximum
130.32
+1 STD
69.50
Minimum
12.36
-1 STD
4.09
Average
36.80

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Fintech (Singapore) Pte. Ltd.
Email Address:
uservice@ttm.financial
User Agreement|Privacy Policy

Copyright © Tiger Fintech (Singapore) Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.